Nitric Oxide and Cardiac Remodeling

Heart Failure Clinics

Volumn 1, Issue 2, 2005, Pages 275-286

  Passeri, Jonathan ^a   Bloch, Kenneth D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGININE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; COLLAGEN; DACTINOMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOPRENALINE; ISOSORBIDE DINITRATE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; N6 (1 IMINOETHYL)LYSINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RAMIPRILAT; S METHYLISOTHIOUREA SULFATE; SCLEROPROTEIN; SUPEROXIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CALCIUM CELL LEVEL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; FIBROSING ALVEOLITIS; HEART CONTRACTION; HEART EXCITATION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; MITOCHONDRIAL RESPIRATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; MYOCYTES, CARDIAC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VENTRICULAR REMODELING;

EID: 33751172737     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.04.002     Document Type: Review

References (98)

1. Pfeffer M.A., and Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81 4 (1990) 1161-1172
2. White H.D., Norris R.M., Brown M.A., et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76 1 (1987) 44-51
3. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 10 (1992) 669-677
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 5 (1991) 293-302
5. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 5 (1991) 303-310
6. Ho K.K., Anderson K.M., Kannel W.B., et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88 1 (1993) 107-115
7. Rodeheffer R.J., Jacobsen S.J., Gersh B.J., et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 68 12 (1993) 1143-1150
8. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 5789 (1980) 373-376
9. Fukuchi M., Hussain S.N., and Giaid A. Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in end-stage human heart failure: their relation to lesion site and beta-adrenergic receptor therapy. Circulation 98 2 (1998) 132-139
10. Heymes C., Vanderheyden M., Bronzwaer J.G., et al. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 99 23 (1999) 3009-3016
11. Qi X.L., Stewart D.J., Gosselin H., et al. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation 100 12 (1999) 1338-1345
12. Drexler H. Nitric oxide synthases in the failing human heart: a doubled-edged sword?. Circulation 99 23 (1999) 2972-2975
13. Prabhu S.D. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res 94 9 (2004) 1155-1157
14. Cohn J.N., Ferrari R., and Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On behalf of the International Forum on Cardiac Remodeling. J Am Coll Cardiol 35 3 (2000) 569-582
15. Sutton M.G., and Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101 25 (2000) 2981-2988
16. Lorell B.H., and Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102 4 (2000) 470-479
17. Braunwald E., and Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 102 20 Suppl 4 (2000) 14-23
18. Molkentin J.D., and Dorn II I.G. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001) 391-426
19. Sam F., Sawyer D.B., Chang D.L., et al. Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am J Physiol Heart Circ Physiol 279 1 (2000) H422-H428
20. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335 16 (1996) 1182-1189
21. Elsasser A., Vogt A.M., Nef H., et al. Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death. J Am Coll Cardiol 43 12 (2004) 2191-2199
22. Olivetti G., Quaini F., Sala R., et al. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 28 9 (1996) 2005-2016
23. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. N Engl J Med 336 16 (1997) 1131-1141
24. Schnee J.M., and Hsueh W.A. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res 46 2 (2000) 264-268
25. Hare J.M. Nitric oxide and excitation-contraction coupling. J Mol Cell Cardiol 35 7 (2003) 719-729
26. Stamler J.S., Lamas S., and Fang F.C. Nitrosylation: the prototypic redox-based signaling mechanism. Cell 106 6 (2001) 675-683
27. Casadei B., and Sears C.E. Nitric-oxide-mediated regulation of cardiac contractility and stretch responses. Prog Biophys Mol Biol 82 1-3 (2003) 67-80
28. Champion H.C., Skaf M.W., and Hare J.M. Role of nitric oxide in the pathophysiology of heart failure. Heart Fail Rev 8 1 (2003) 35-46
29. Massion P.B., Feron O., Dessy C., et al. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 93 5 (2003) 388-398
30. Matsuoka H., Nakata M., Kohno K., et al. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 27 1 (1996) 14-18
31. Calderone A., Thaik C.M., Takahashi N., et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101 4 (1998) 812-818
32. Ritchie R.H., Schiebinger R.J., LaPointe M.C., et al. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol 275 4 Pt 2 (1998) H1370-H1374
33. Oyama J., Frantz S., Blais Jr. C., et al. Nitric oxide, cell death, and heart failure. Heart Fail Rev 7 4 (2002) 327-334
34. Li J., Billiar T.R., Talanian R.V., et al. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 240 2 (1997) 419-424
35. Genaro A.M., Hortelano S., Alvarez A., et al. Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. J Clin Invest 95 4 (1995) 1884-1890
36. Wink D.A., Hanbauer I., Krishna M.C., et al. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci U S A 90 21 (1993) 9813-9817
37. Lepoivre M., Flaman J.M., Bobe P., et al. Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. Relationship to cytostasis induced in tumor cells by cytotoxic macrophages. J Biol Chem 269 34 (1994) 21891-21897
38. Messmer U.K., Ankarcrona M., Nicotera P., et al. p53 expression in nitric oxide-induced apoptosis. FEBS Lett 355 1 (1994) 23-26
39. Forrester K., Ambs S., Lupold S.E., et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A 93 6 (1996) 2442-2447
40. Pinsky D.J., Aji W., Szabolcs M., et al. Nitric oxide triggers programmed cell death (apoptosis) of adult rat ventricular myocytes in culture. Am J Physiol 277 3 Pt 2 (1999) H1189-H1199
41. Xia Z., Dickens M., Raingeaud J., et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 5240 (1995) 1326-1331
42. Ing D.J., Zang J., Dzau V.J., et al. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 84 1 (1999) 21-33
43. Kim N.N., Villegas S., Summerour S.R., et al. Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide. J Mol Cell Cardiol 31 2 (1999) 457-466
44. Granger D.L., Taintor R.R., Cook J.L., et al. Injury of neoplastic cells by murine macrophages leads to inhibition of mitochondrial respiration. J Clin Invest 65 2 (1980) 357-370
45. Hibbs Jr. J.B., Taintor R.R., Vavrin Z., et al. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157 1 (1988) 87-94
46. Stuehr D.J., and Nathan C.F. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169 5 (1989) 1543-1555
47. Raczniak T.J., Chesney C.F., and Allen J.R. Oxidative phosphorylation and respiration by mitochondria from normal, hypertrophied and failing rat hearts. J Mol Cell Cardiol 9 3 (1977) 215-223
48. Maurer I., and Zierz S. Myocardial respiratory chain enzyme activities in idiopathic dilated cardiomyopathy, and comparison with those in atherosclerotic coronary artery disease and valvular aortic stenosis. Am J Cardiol 72 5 (1993) 428-433
49. Trochu J.N., Bouhour J.B., Kaley G., et al. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 87 12 (2000) 1108-1117
50. Loke K.E., Laycock S.K., Mital S., et al. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation 100 12 (1999) 1291-1297
51. Chen Y., Traverse J.H., Du R., et al. Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation 106 2 (2002) 273-279
52. Walsh E.K., Huang H., Wang Z., et al. Control of myocardial oxygen consumption in transgenic mice overexpressing vascular eNOS. Am J Physiol Heart Circ Physiol 287 5 (2004) H2115-H2121
53. Takemoto M., Egashira K., Usui M., et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99 2 (1997) 278-287
54. Pechanova O., Bernatova I., Pelouch V., et al. L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol Res 48 5 (1999) 353-362
55. Bartunek J., Weinberg E.O., Tajima M., et al. Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systolic load in absence of hypertrophy. Circulation 101 4 (2000) 423-429
56. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 343 8906 (1994) 1115-1122
57. Mahmarian J.J., Moye L.A., Chinoy D.A., et al. Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial. Circulation 97 20 (1998) 2017-2024
58. Wittstein I.S., Kass D.A., Pak P.H., et al. Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy. J Am Coll Cardiol 38 2 (2001) 429-435
59. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 20 (2004) 2049-2057
60. Cotter G., Kaluski E., Blatt A., et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 101 12 (2000) 1358-1361
61. Barouch L.A., Harrison R.W., Skaf M.W., et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416 6878 (2002) 337-339
62. Xu K.Y., Huso D.L., Dawson T.M., et al. Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci U S A 96 2 (1999) 657-662
63. Campbell D.L., Stamler J.S., and Strauss H.C. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 108 4 (1996) 277-293
64. Xu L., Eu J.P., Meissner G., et al. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279 5348 (1998) 234-237
65. Eu J.P., Sun J., Xu L., et al. The skeletal muscle calcium release channel: coupled O2 sensor and NO signaling functions. Cell 102 4 (2000) 499-509
66. Cohen R.A., Weisbrod R.M., Gericke M., et al. Mechanism of nitric oxide-induced vasodilatation: refilling of intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition of store-operated Ca2+ influx. Circ Res 84 2 (1999) 210-219
67. Dedkova E.N., and Blatter L.A. Nitric oxide inhibits capacitative Ca2+ entry and enhances endoplasmic reticulum Ca2+ uptake in bovine vascular endothelial cells. J Physiol 539 Pt 1 (2002) 77-91
68. Trepakova E.S., Cohen R.A., and Bolotina V.M. Nitric oxide inhibits capacitative cation influx in human platelets by promoting sarcoplasmic/endoplasmic reticulum Ca2+-ATPase-dependent refilling of Ca2+ stores. Circ Res 84 2 (1999) 201-209
69. Adachi T., Weisbrod R.M., Pimentel D.R., et al. S-glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 10 11 (2004) 1200-1207
70. Bendall J.K., Damy T., Ratajczak P., et al. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 110 16 (2004) 2368-2375
71. Damy T., Ratajczak P., Shah A.M., et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 363 9418 (2004) 1365-1367
72. Ferdinandy P., Danial H., Ambrus I., et al. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87 3 (2000) 241-247
73. de Belder A.J., Radomski M.W., Why H.J., et al. Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvar heart disease. Br Heart J 74 4 (1995) 426-430
74. Haywood G.A., Tsao P.S., von der Leyen H.E., et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 93 6 (1996) 1087-1094
75. Lewis N.P., Tsao P.S., Rickenbacher P.R., et al. Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 93 4 (1996) 720-729
76. Paulus W.J., Kastner S., Pujadas P., et al. Left ventricular contractile effects of inducible nitric oxide synthase in the human allograft. Circulation 96 10 (1997) 3436-3442
77. Wildhirt S.M., Suzuki H., Wolf W.P., et al. S-methylisothiourea inhibits inducible nitric oxide synthase and improves left ventricular performance after acute myocardial infarction. Biochem Biophys Res Commun 227 2 (1996) 328-333
78. Feng Q., Lu X., Jones D.L., et al. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 104 6 (2001) 700-704
79. Sam F., Sawyer D.B., Xie Z., et al. Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res 89 4 (2001) 351-356
80. Jones S.P., Greer J.J., Ware P.D., et al. Deficiency of iNOS does not attenuate severe congestive heart failure in mice. Am J Physiol Heart Circ Physiol 288 1 (2005) H365-H370
81. Parker M.M., Shelhamer J.H., Bacharach S.L., et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100 4 (1984) 483-490
82. Parrillo J.E. Pathogenetic mechanisms of septic shock. N Engl J Med 328 20 (1993) 1471-1477
83. Ullrich R., Scherrer-Crosbie M., Bloch K.D., et al. Congenital deficiency of nitric oxide synthase 2 protects against endotoxin-induced myocardial dysfunction in mice. Circulation 102 12 (2000) 1440-1446
84. Ichinose F., Hataishi R., Wu J.C., et al. A selective inducible NOS dimerization inhibitor prevents systemic, cardiac, and pulmonary hemodynamic dysfunction in endotoxemic mice. Am J Physiol Heart Circ Physiol 285 6 (2003) H2524-H2530
85. Mungrue I.N., Gros R., You X., et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 109 6 (2002) 735-743
86. Heger J., Godecke A., Flogel U., et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 90 1 (2002) 93-99
87. Balligand J.L., Kelly R.A., Marsden P.A., et al. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A 90 1 (1993) 347-351
88. Balligand J.L., Kobzik L., Han X., et al. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 270 24 (1995) 14582-14586
89. Kelly R.A., Balligand J.L., and Smith T.W. Nitric oxide and cardiac function. Circ Res 79 3 (1996) 363-380
90. Anderson R.G. Caveolae: where incoming and outgoing messengers meet. Proc Natl Acad Sci U S A 90 23 (1993) 10909-10913
91. Barouch L.A., Cappola T.P., Harrison R.W., et al. Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol 35 6 (2003) 637-644
92. Ozaki M., Kawashima S., Yamashita T., et al. Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 66 9 (2002) 851-856
93. Ortiz M.I., Torres-Lopez J.E., Castaneda-Hernandez G., et al. Role of the nitric oxide-cyclic GMP-K+ channel pathway in the antinociception induced by atrial natriuretic peptide (ANP) and diclofenac. Proc West Pharmacol Soc 45 (2002) 174-177
94. Ichinose F., Bloch K.D., Wu J.C., et al. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol 286 3 (2004) H1070-H1075
95. Scherrer-Crosbie M., Ullrich R., Bloch K.D., et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 104 11 (2001) 1286-1291
96. Liu Y.H., Xu J., Yang X.P., et al. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension 39 2 Pt 2 (2002) 375-381
97. Jones S.P., Greer J.J., van Haperen R., et al. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci U S A 100 8 (2003) 4891-4896
98. Janssens S., Pokreisz P., Schoonjans L., et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 94 9 (2004) 1256-1262